NOSE ACADEMY CIC

Company limited by guarantee

Company Registration Number:
12954601 (England and Wales)

Unaudited statutory accounts for the year ended 29 October 2025

Period of accounts

Start date: 30 October 2024

End date: 29 October 2025

NOSE ACADEMY CIC

Contents of the Financial Statements

for the Period Ended 29 October 2025

Directors report
Profit and loss
Balance sheet
Additional notes
Balance sheet notes
Community Interest Report

NOSE ACADEMY CIC

Directors' report period ended 29 October 2025

The directors present their report with the financial statements of the company for the period ended 29 October 2025

Principal activities of the company

The principal activity of the company during the year under review was Educational Support services. The principal activity of the CIC was to promote education and professional development in rhinology and related areas of ENT surgery.



Directors

The director shown below has held office during the whole of the period from
30 October 2024 to 29 October 2025

Shahzada K Ahmed


The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006

This report was approved by the board of directors on
23 July 2026

And signed on behalf of the board by:
Name: Shahzada K Ahmed
Status: Director

NOSE ACADEMY CIC

Profit And Loss Account

for the Period Ended 29 October 2025

2025 2024


£

£
Turnover: 35,141 27,577
Cost of sales: 0 0
Gross profit(or loss): 35,141 27,577
Administrative expenses: ( 36,304 ) ( 33,371 )
Operating profit(or loss): (1,163) (5,794)
Profit(or loss) before tax: (1,163) (5,794)
Profit(or loss) for the financial year: (1,163) (5,794)

NOSE ACADEMY CIC

Balance sheet

As at 29 October 2025

Notes 2025 2024


£

£
Fixed assets
Tangible assets: 3 921 1,084
Total fixed assets: 921 1,084
Current assets
Cash at bank and in hand: 14,618 7,349
Total current assets: 14,618 7,349
Creditors: amounts falling due within one year: 4 ( 13,748 ) ( 5,479 )
Net current assets (liabilities): 870 1,870
Total assets less current liabilities: 1,791 2,954
Total net assets (liabilities): 1,791 2,954
Members' funds
Profit and loss account: 1,791 2,954
Total members' funds: 1,791 2,954

The notes form part of these financial statements

NOSE ACADEMY CIC

Balance sheet statements

For the year ending 29 October 2025 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 23 July 2026
and signed on behalf of the board by:

Name: Shahzada K Ahmed
Status: Director

The notes form part of these financial statements

NOSE ACADEMY CIC

Notes to the Financial Statements

for the Period Ended 29 October 2025

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

    Turnover policy

    Turnover is measured at the fair value of the consideration received or receivable.

    Other accounting policies

    Intangible fixed assets are carried at cost less accumulated amortisation and impairment losses. Research and development costs Expenditure on research and development is written off in the year it is incurred unless it meets the criteria to allow it to be capitalised. Costs of research are always written off in the year in which they are incurred. Where development costs are recognised as an asset, they are amortised over the period expected to benefit from them. Amortisation of the capitalised costs begins once the developed product comes into use, typically at rate of 33.33% straight line. Taxation Income tax expense represents the sum of the tax currently payable and deferred tax. The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the profit and loss account because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The Company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period. Deferred tax is recognised on timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable temporary differences. Deferred tax assets are generally recognised for all deductible timing differences to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Current or deferred tax for the year is recognised in profit or loss, except when they relate to items that are recognised in other comprehensive income or directly in equity, in which case, the current and deferred tax is also recognised in other comprehensive income or directly in equity respectively. Freehold investment property Investment properties are revalued annually and any surplus or deficit is dealt with through the profit and loss account. No depreciation is provided in respect of investment properties. Investments Unlisted investments (except those held as subsidiaries, associates or joint ventures) are recognised initially at fair value less attributable transaction costs. Subsequent to initial recognition, any changes in fair value are recognised in profit and loss.

NOSE ACADEMY CIC

Notes to the Financial Statements

for the Period Ended 29 October 2025

  • 2. Employees

    2025 2024
    Average number of employees during the period 1 1

NOSE ACADEMY CIC

Notes to the Financial Statements

for the Period Ended 29 October 2025

3. Tangible assets

Land & buildings Plant & machinery Fixtures & fittings Office equipment Motor vehicles Total
Cost £ £ £ £ £ £
At 30 October 2024 1,500 1,500
Additions
Disposals
Revaluations
Transfers
At 29 October 2025 1,500 1,500
Depreciation
At 30 October 2024 416 416
Charge for year 163 163
On disposals
Other adjustments
At 29 October 2025 579 579
Net book value
At 29 October 2025 921 921
At 29 October 2024 1,084 1,084

NOSE ACADEMY CIC

Notes to the Financial Statements

for the Period Ended 29 October 2025

4. Creditors: amounts falling due within one year note

2025 2024
£ £
Taxation and social security 1,963 1,963
Accruals and deferred income 2,760 1,260
Other creditors 9,025 2,256
Total 13,748 5,479

COMMUNITY INTEREST ANNUAL REPORT

NOSE ACADEMY CIC

Company Number: 12954601 (England and Wales)

Year Ending: 29 October 2025

Company activities and impact

During the financial year ending 31/10/25, Nose Academy CIC promoted education and professional development in rhinology and related areas of ENT surgery. The company delivered teaching, lectures, specialist courses and cadaveric dissection training for rhinology trainees and other healthcare professionals at both national and international levels. It also supported the dissemination of clinical knowledge by presenting academic research at professional meetings and participating in rhinology conferences. These activities benefited the healthcare community by improving access to specialist education, developing clinical and surgical skills, encouraging the exchange of best practice and ultimately supporting higher standards of patient care.

Consultation with stakeholders

Nose Academy’s stakeholders include patients, the public, healthcare professionals, trainees, educational contributors and partner healthcare organisations. Feedback has been gathered through informal discussions, professional meetings, educational activities and direct comments. In response, Nose Academy has refined its content, prioritised relevant topics and ensured its education remains accessible, evidence-based, patient-centred and focused on public benefit.

Directors' remuneration

No remuneration was received

Transfer of assets

No transfer of assets other than for full consideration

This report was approved by the board of directors on
23 July 2026

And signed on behalf of the board by:
Name: S K Ahmed
Status: Director